Drug Discovery
Drug discovery is the process by which new potential medications are identified, involving the identification of Biomarkers, drug targets, and the screening of chemical compounds or Biologics for their therapeutic effects. The pipeline typically progresses from target identification to lead optimization, preclinical testing, and clinical trials.
Key Processes
- Target Identification: Using Genomics and Proteomics to find biological targets associated with disease.
- Hit Identification: High-throughput screening (HTS) or virtual screening to find initial active compounds.
- Lead Optimization: Modifying chemical structures to improve efficacy, safety, and pharmacokinetics.
- Preclinical Development: In vitro and in vivo testing for toxicity and efficacy.
Technological Integration & AI
Artificial Intelligence is increasingly central to accelerating discovery timelines and reducing costs. Recent developments highlight the broader integration of AI in healthcare systems, which impacts how data is generated and interpreted for drug development.
- Shadow AI Integration: The rapid, often unregulated adoption of AI tools in clinical settings creates a “shadow” layer of decision-making that outpaces systemic oversight. This phenomenon, detailed in Shadow AI: Rapid Integration in Healthcare, Diagnostic Benefits, and System Challenges, suggests that diagnostic benefits are being realized faster than regulatory frameworks can adapt.
- Diagnostic Data Feedback: Improved diagnostic accuracy via AI and robotics provides higher-quality phenotypic data, which can refine target validation in early-stage discovery.
- Systemic Challenges: The disparity between the speed of AI-driven diagnostics/robotics and institutional bureaucracy poses risks for data standardization, which is critical for training robust machine-learning models in drug discovery.